Literature DB >> 22170044

Impact of age and heterophilic interference on the basal serum tryptase, a risk indication for anaphylaxis, in 1,092 dermatology patients.

Sibylle Schliemann1, Florian Seyfarth, Uta-Christina Hipler, Peter Elsner.   

Abstract

A raised baseline serum tryptase is a risk indicator for anaphylactic reactions, especially in patients with hymenoptera venom allergy. Borderline elevations (> 11.4 μg/l) occur frequently and may necessitate invasive diagnostic procedures to rule out systemic mastocytosis. We retrospectively analysed 1,092 non-mastocytotic patients from our general dermatology clinic with respect to age- and gender-associated effects and investigated the impact of heterophilic antibody interference on the tryptase assay. The results were stratified by gender and five age classes. Sera with raised tryptase (n = 106) were re-tested after pre-incubation with Heterophilic Blocking Tubes (HBT(®), Scantibodies Laboratory; Santee, CA, USA). A significant increase in baseline tryptase was observed with increasing age. Incubation with HBT(®) caused a decline of more than 50% in only one case. In conclusion, older patients showed significantly higher serum tryptase levels and heterophilic interference was of subordinate relevance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22170044     DOI: 10.2340/00015555-1245

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  3 in total

Review 1.  [Value of in-vitro diagnostic tools after anaphylaxis].

Authors:  L Vanstreels; H F Merk
Journal:  Hautarzt       Date:  2013-02       Impact factor: 0.751

2.  Effect of body mass index and rocuronium on serum tryptase concentration during volatile general anesthesia: an observational study.

Authors:  Urszula Kosciuczuk; Pawel Knapp; Piotr Jakubow
Journal:  Clinics (Sao Paulo)       Date:  2020-08-10       Impact factor: 2.365

Review 3.  The serum tryptase test: an emerging robust biomarker in clinical hematology.

Authors:  Peter Valent; Wolfgang R Sperr; Karl Sotlar; Andreas Reiter; Cem Akin; Jason Gotlib; Hans-Peter Horny; Michel Arock
Journal:  Expert Rev Hematol       Date:  2014-08-28       Impact factor: 2.929

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.